Table 1 Demographic characteristics of raters
Participant Characteristics Questions | Response Choices | Frequency | % |
|---|---|---|---|
Years Involved | 0–5 years | 52 | 17% |
|  | 6–10 years | 60 | 19% |
|  | 11–15 years | 73 | 24% |
|  | 16–20 years | 81 | 26% |
| Â | Longer than 20 years | 38 | 12% |
| Â | did not respond | 4 | 1% |
| Â | Â | 308 | 100.00% |
Primary Area of Science | Vaccine Research & Development | 53 | 17% |
| Â | Translational Research/Drug Development | 38 | 12% |
| Â | Optimization of Clinical Management, including Co- Morbidities | 112 | 36% |
| Â | Microbicides | 17 | 6% |
| Â | Prevention of Mother- to- Child Transmission of HIV | 23 | 7% |
| Â | Prevention of HIV Infection | 23 | 7% |
| Â | Other/Not applicable | 38 | 12% |
| Â | did not respond | 4 | 1% |
| Â | Â | 308 | 100.00% |
Primary Role | Network Core | 81 | 26% |
| Â | Clinical Trials Unit/Site | 107 | 35% |
| Â | Laboratory | 14 | 5% |
| Â | Government | 47 | 15% |
| Â | Community | 12 | 4% |
| Â | Pharma/Biotech | 2 | 1% |
| Â | Pharmacy | 2 | 1% |
| Â | Institutional Review Board/Ethics Committee | 0 | 0% |
| Â | Non- Governmental Organization | 10 | 3% |
| Â | Advisory Group/Committee | 6 | 2% |
| Â | Other | 23 | 7% |
| Â | did not respond | 4 | 1% |
| Â | Â | 308 | 100.00% |